Oric Pharmaceuticals stock under sustained selling pressure, trades near new support zone

Traders Union
All News
Companies
Oric Pharmaceuticals drops 12.47% today

All news

Editors' Picks

Crypto News

Financial News

Market Voices

Billionaires

Companies

Broker News

Regulators News

Emilio Ghigini

Yesterday

Oric Pharmaceuticals stock under sustained selling pressure, trades near new support zone — Oric Pharmaceuticals drops 12.47% today

Oric Pharmaceuticals said President and CEO Jacob Chacko and CFO Dom Piscitelli will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, at 11:40 a.m. ET.

A live or archived recording of the discussion will be available at the provided link. The company announced the event on social media.

Highlights

ORIC trades below all major moving averages, signaling persistent bearish momentum across short, medium, and long terms.
Momentum indicators confirm a strong sell bias, with broad weakness and overbought readings highlighting heavy selling pressure.
Expected range next week is $7.50 to $8.25, with resistance above $8.25 and increased risk of testing the 52-week low if selling persists.

Persistent bearish bias as price holds below major moving averages

ORIC is currently trading at $7.86, which is below both the MA-20 ($8.66), MA-50 ($9.71), and MA-200 ($10.82), reflecting a persistent bearish bias in the short, medium, and longer-term trend structure. The Ichimoku Kijun on D1 is at $9.14, marking immediate resistance. Near-term support is found at the MA-20 level ($8.66), with key support at the MA-50 ($9.71), while immediate resistance sits at the Ichimoku Kijun ($9.14) and key resistance at MA-100 ($10.59).

Sustained downside pressure as momentum turns decisively negative

Momentum readings are negative: MACD on D1 signals a strong sell, and ADX at 17.36 indicates a weak trend. RSI on D1 sits just below 50 and is aligned with a sell signal, while Stoch RSI remains overbought but several shorter timeframes now show oversold conditions. BBP also reads overbought, yet its direction and value suggest persistent downward pressure from sellers intraday. CCI is neutral but leans to oversold on multiple timeframes. ORIC has declined $0.59 (6.71%) from last week's close of $8.45 and is trading at the very bottom of this week’s range, with weekly volatility at 10.55%. The tone is a steady decline from recent highs. In today's session, the stock dropped sharply by 12.47%, underlining heavy selling pressure.

Bearish continuation likely as support zone faces renewed test

Looking ahead, the expected trading range for the next week is $7.50 to $8.25, which is just above the 52-week low of $7.37 and well below the 52-week high of $14.93. The probabilities derived from weekly indicators show a very low probability (less than 20%) of a price increase next week, making a further decline more likely. The baseline scenario anticipates consolidation between $7.50 and $8.25 as the stock trades close to its support zone. A bullish scenario would require a sustained move above $8.25–$8.66 (near-term and MA-20 resistance), while a bearish scenario could see a test of $7.50 and potentially the 52-week low if selling persists.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Oric Pharmaceuticals' rinzimetostat (ORIC-944) was selected for presentation at an upcoming AACR meeting, highlighting its potential in prostate cancer treatment. Investors should monitor for further clinical updates, as progress on rinzimetostat remains a key scenario influencing near-term sentiment around Oric Pharmaceuticals.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.